DR. HASKELL MCGILL KIRKPATRICK MD NPI 1356384200

NPI Details

DR. Haskell Mcgill Kirkpatrick, MD is a medical oncology internal medicine in Dallas, TX with 26 years of experience. The provider is an internist who specializes in the diagnosis and treatment of all types of cancer and other benign and malignant tumors. This specialist decides on and administers therapy for these malignancies as well as consults with surgeons and radiotherapists on other treatments for cancer. DR. Haskell Mcgill Kirkpatrick, MD NPI is 1356384200. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

Education
Medical School: UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL SCHOOL AT DALLAS
Graduation Year:2000

The provider's business location address is:

8196 WALNUT HILL LN STE 100
DALLAS, TX
ZIP 75231-001
Phone: (214) 739-4175
Fax: (214) 346-3541

The NPI 1356384200 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, iron sucrose, 1 mg (HCPCS:J1756)
• Injection, darbepoetin alfa, 1 microgram (non-esrd use) (HCPCS:J0881)
• Injection, fosaprepitant, 1 mg (HCPCS:J1453)
• Injection, oxaliplatin, 0.5 mg (HCPCS:J9263)
• Injection, nivolumab, 1 mg (HCPCS:J9299)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg (HCPCS:J1568)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg (HCPCS:Q5118)
• Injection, bortezomib (velcade), 0.1 mg (HCPCS:J9041)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, pemetrexed, not otherwise specified, 10 mg (HCPCS:J9305)
• Injection, trastuzumab-anns, biosimilar, (kanjinti), 10 mg (HCPCS:Q5117)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg (HCPCS:Q5119)
• Blood test, comprehensive group of blood chemicals (HCPCS:80053)
• Injection, granisetron hydrochloride, 100 mcg (HCPCS:J1626)
• Injection, gadobutrol, 0.1 ml (HCPCS:A9585)
• Injection, atropine sulfate, 0.01 mg (HCPCS:J0461)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Injection, fulvestrant, 25 mg (HCPCS:J9395)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Injection, irinotecan, 20 mg (HCPCS:J9206)
• Injection, pegfilgrastim, excludes biosimilar, 0.5 mg (HCPCS:J2506)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Injection, potassium chloride, per 2 meq (HCPCS:J3480)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Microscopic examination for white blood cells with manual cell count (HCPCS:85007)
• Complete blood cell count (red cells, white blood cell, platelets), automated test (HCPCS:85027)
• Carcinoembryonic antigen (cea) protein level (HCPCS:82378)
• Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Lactate dehydrogenase (enzyme) level (HCPCS:83615)
• Injection, magnesium sulfate, per 500 mg (HCPCS:J3475)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Follow-up hospital inpatient care per day, typically 25 minutes (HCPCS:99232)
• Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a (HCPCS:G9678)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Ferritin (blood protein) level (HCPCS:82728)
• Iron level (HCPCS:83540)
• Iron binding capacity (HCPCS:83550)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Unclassified drugs (HCPCS:J3490)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 19-9 (HCPCS:86301)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Injection of drug or substance into vein (HCPCS:96374)
• Blood test, basic group of blood chemicals (calcium, total) (HCPCS:80048)
• Psa (prostate specific antigen) measurement, total (HCPCS:84153)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
• Drawing of blood for a medical problem (HCPCS:99195)
• Leuprolide acetate (for depot suspension), 7.5 mg (HCPCS:J9217)
• Irrigation of implanted venous access drug delivery device (HCPCS:96523)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Application of on-body injector for under skin injection (HCPCS:96377)
• Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries (HCPCS:A9552)
• Follow-up hospital inpatient care per day, typically 15 minutes (HCPCS:99231)
• Nuclear medicine study from skull base to mid-thigh with ct scan (HCPCS:78815)
• New patient office or other outpatient visit, 30-44 minutes (HCPCS:99203)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Infusion, normal saline solution, sterile (500 ml = 1 unit) (HCPCS:J7040)
• Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
• Follow-up hospital inpatient care per day, typically 35 minutes (HCPCS:99233)
• Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:M0220)

The enumeration date for this NPI number is 6/14/2006 and was last updated on 7/2/2025.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.